PFE - Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance WHO Report Says | Benzinga
The World Health Organization (WHO) released its latest HIV Drug Resistance (HIVDR) Report, shedding light on the growing areas of drug resistance and providing crucial recommendations for countries to navigate potential challenges.
The report carried both optimistic and concerning revelations, highlighting high levels of HIV viral load suppression in populations undergoing dolutegravir (DTG)-containing antiretroviral therapy (ART).
It also raised alarms about increasing levels of drug resistance to dolutegravir beyond clinical trial observations.
ViiV Healthcare, majority owned by GSK plc (NYSE:GSK), as well as owned by Pfizer Inc (NYSE:PFE) and Shionogi, sells dolutegravir under the Tivicay ...